Authors
Latest:
Determining Treatment Options for Select Subsets of Neuroendocrine TumorsThor Halfdanarson, MD, discusses his takeaway message on neuroendocrine tumors (NETs) at the 2018 ISGIO Annual Conference.
Latest:
Overall Survival Update for KEYNOTE-564 in Renal Cell CarcinomaTian Zhang, MD, and the Oncology Brothers offer comprehensive insights on the overall survival update for KEYNOTE-564 in renal cell carcinoma.
Latest:
Recognizing Subsets of Triple-Negative Breast CancerTiffany A. Traina, MD, a medical oncologist at Weill Cornell Medicine, discusses the current treatment landscape for patients with triple-negative breast cancer.
Latest:
Abscopal Effect Induction Among Patients With Metastatic Non-Small Cell Lung CancerThe prognosis for patients with metastatic non–small cell lung cancer (NSCLC) is poor. However, with recent trials showing improved overall survival with checkpoint inhibitors compared with standard chemotherapy, disease management is changing.
Latest:
The Possibility for Immunotherapy in Liver CancerTim F. Greten, MD, senior investigator, Thoracic and Gastrointestinal Oncology Branch, and head, Gastrointestinal Malignancy Section, National Cancer Institute Center for Cancer Research, discusses the possibility for immunotherapy in liver cancer.
Latest:
Sequencing Therapies in Patients With Rectal Cancer and a Single Lung NoduleTimil Patel, MD, discusses how to sequence therapies in a patient with rectal cancer with a single lung nodule.
Latest:
NGS Testing Necessary for Treatment of Lung AdenocarcinomaTimothy F. Burns, MD, PhD, discusses the necessary role of next-generation sequencing testing in patients with lung adenocarcinoma. In order to incorporate this into clinical practice, there is still a lot more work to be done, Burns says. Around 20% to 25% of patients with adenocarcinoma have targetable alterations.
Latest:
Comorbidities, Age, and Outcomes Among Intensively Treated Patients With AMLTimothy S. Pardee, MD, discusses comorbidities, age, and outcomes among intensively treated patients with acute myeloid leukemia (AML).
Latest:
What is Lung Suffusion?Todd Demmy, MD, clinical chair, Department of Thoracic Surgery, professor of oncology, Roswell Park Cancer Institute, describes lung suffusion.
Latest:
Measuring Quality and Value With Oncology Pharmacy AccreditationTodd Murphree, PharmD, pharmacist, Clearview Cancer Institute, discusses measuring the quality and value of having oncology pharmacy accreditation.
Latest:
Examining mCRC Chemotherapy Costs, Patient Outcomes in Washington vs British ColumbiaTodd Yezefski, MD, a senior fellow in the Clinical Research Division at the Fred Hutchinson Cancer Research Center, discusses the results of a trial investigating cost and outcome differences in patients with metastatic colorectal cancer in the United States and Canada. Specifically, he looked at patients in Washington and British Columbia. This data was presented at the 2018 ASCO Annual Meeting.
Latest:
Immune Checkpoint Inhibition in Esophagogastric CancersThe poor prognosis for patients with esophagogastric cancers (EGC) requires the development of newer more effective therapies to further improve the treatment outcomes for this disease. Immunotherapy is a novel treatment strategy that is dramatically changing the treatment landscape for several types of cancers. Cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody and antagonists of the programmed death (PD)-1/PD-ligand 1 are essential immune checkpoint inhibitors that suppress T-cell activation.
Latest:
Characterization of Immune-Related Adverse Events of Ipilimumab Versus Placebo in mCRPCTomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.
Latest:
Future Directions for the Treatment of mCRPCTomasz M. Beer, MD, FACP, shares unmet needs and clinical pearls for the management of patients with mCRPC.
Latest:
Tivozanib Outperforms ICI Combo in Advanced RCCToni Choueiri, MD, discusses the rationale behind the drug combination of tivozanib and nivolumab in the TiNivo-2 study.
Latest:
PSMAfore: Health-Related QoL and Pain in Taxane-Naïve Patients with mCRPCToni Choueiri, MD, and the Oncology Brothers discuss the PSMAfore study evaluating health-related quality of life and pain in taxane-naïve patients with metastatic castration-resistant prostate cancer.
Latest:
Three of 4 Molecular Subgroups Respond to Dostarlimab in Advanced Endometrial CarcinomaFindings from the ENGOT-EN6-NSGO/GOG-3031/RUBY trial showed that patients with dMMR/MSI-H had a progression-free survival rate of 57.0% in the dostarlimab arm vs 10.2% in the placebo arm.
Latest:
The Targeted Pulse: Discover Upcoming Meetings, FDA Action, and Key Insights in SCLC and mCSPCThe 22nd Annual Winter Lung Cancer Conference® will explore advances in neoadjuvant/adjuvant therapies. The FDA has approved Obe-cel for R/R B-ALL, and new treatments in SCLC, lurbinectedin and tarlatamab, show promise. Apalutamide tops enzalutamide in real-world data for mCSPC, and LBL-034 gains orphan drug designation for multiple myeloma.
Latest:
Genetic Testing is Essential in NSCLC Prior to Induction TherapyTesting for driver mutations is essential before initiating therapy in patients with non–small cell lung cancer, because there is a risk that the type of upfront treatment chosen could add to the toxicity of, and spur resistance to, targeted therapy options, Suresh S. Ramalingam, MD, said at the 14th Annual New York Lung Cancers Symposium.
Latest:
Dr. Mok Discusses Next Steps With Pembrolizumab in NSCLCTony Mok, MD, discusses the next steps for pembrolizumab (Keytruda) as a treatment option for patients with non-small cell lung cancer after the phase III KEYNOTE-042 trial.
Latest:
Analyzing the ADAURA Trial of Osimertinib in EGFR+ Lung CancerTony S. K. Mok, BMSc, MD, FRCPC, discusses the ADAURA trial of osimertinib in patients with non–small cell lung cancer.
Latest:
The Challenges of Using Ki67 as a Tool in Breast CancerTorsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the difficulties when using Ki67 to measure proliferation in breast cancer.
Latest:
Q & A With Kimberly L. Blackwell: The Treatment of HER2 Metastatic Breast CancerSince its approval in 1998 to treat metastatic disease, trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive breast cancer.
Latest:
Quality of Life as a Predictor of Clinical Outcome in Patients With HNCTrisha Wise-Draper, MD, PhD, assistant professor, University of Cincinnati, discusses the quality of life (QOL) as a predictor of clinical outcome in patients with head and neck cancer (HNC).
Latest:
Dr. Tuya Pal on Genetic Risk Assessment in Ovarian CancerTuya Pal, MD, discusses the importance of genetic risk assessment shaping management guidelines in ovarian cancer.
Latest:
Next Steps for Acalabrutinib in MCLThe results of a phase 1b trial looking at the use of acalabrutinib for patients with treatment-naive or relapsed/refractory mantle cell lymphoma has provided the support needed for the phase 3 ECHO study of this treatment.
Latest:
Updated Response Findings With Larotrectinib in TRK+ CancersUlrik Lassen, MD, PhD, discusses the updated response findings with larotrectinib in TRK+ cancers.
Latest:
Analyzing the Survival Benefits of Niraparib Dose Modification in Ovarian CancerUrsula A. Matulonis, MD, discusses the survival results from an analysis of the QUADRA trial in heavily pretreated patients with recurrent ovarian cancer.
Latest:
An Abundance of PARP Inhibitors are Changing Ovarian Cancer TreatmentUrsula A. Matulonis, MD, discusses the impact of PARP inhibitors on ovarian cancer treatment.
